Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

This article is part of the Research TopicAdvancing Diagnosis and Treatment Strategies for UveitisView all 4 articles

Visual prognosis of Behçet's uveitis patients in China and its associated factors

Provisionally accepted
  • 1The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2Peking Union Medical College Hospital (CAMS), Beijing, China
  • 3The Fourth People's Hospital of Shenyang, Shenyang, Liaoning Province, China

The final, formatted version of the article will be published soon.

Background: Behçet's disease (BD) is a chronic, relapsing, multisystem inflammatory disorder, with ocular involvement being a major cause of irreversible visual impairment. Behçet's uveitis (BU) often presents as bilateral, recurrent, non-granulomatous panuveitis with occlusive retinal vasculitis. Despite advances in immunosuppressive and biologic therapies, long-term visual outcomes remain variable, and factors associated with poor prognosis, particularly in Chinese populations, are not well defined. Methods: We conducted a retrospective cohort study of 153 Chinese patients (268 eyes) with BU at Peking Union Medical College Hospital from February 2003 to February 2023. Clinical records, ocular examinations, and systemic manifestations were reviewed. The primary endpoint was severe visual impairment (best-corrected visual acuity [BCVA] <20/200) at the final follow-up. Secondary endpoints included ocular complications and their impact on visual outcomes. Kaplan–Meier survival analysis and mixed-effects logistic regression (accounting for inter-eye correlation) were used to evaluate risk factors for poor visual prognosis. Results: Among the cohort, 77.8% were male, and bilateral involvement occurred in 84.3%. Median follow-up was 30 months. Panuveitis was the predominant form (90.3%), and cataract (64.9%) and macular edema (63.1%) were the most common complications. At final follow-up, 25.4% of eyes had BCVA <20/200. Kaplan–Meier analysis showed cumulative risk of severe visual loss of 3.5% at 1 year, 11.0% at 2 years, 19.2% at 5 years, and 41.4% at 10 years. Male patients experienced visual impairment earlier than females. Mixed-effects logistic regression identified macular damage (p=0.027, OR=3.70) and optic nerve atrophy (p<0.001, OR=6.47) as significant predictors of poor visual outcomes, while complete-type BD showed a trend toward association (p=0.072, OR=2.00). Systemic disease severity was not significantly associated with visual prognosis. Conclusion: In this Chinese cohort with BU, irreversible ocular structural damage, particularly macular damage and optic nerve atrophy, was the primary determinant of long-term visual outcomes. Systemic disease severity had limited predictive value. Despite improvements compared with historical data, these findings highlight the critical importance of early recognition and effective management of posterior segment inflammation to prevent permanent visual impairment.

Keywords: Behçet's uveitis, biologic therapy, Chinese population, Macular damage, Optic Nerve atrophy, Visual prognosis

Received: 24 Apr 2025; Accepted: 10 Feb 2026.

Copyright: © 2026 Pei, Qian, Liu, Zhao, Gao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Meifen Zhang

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.